Palmitate-induced skeletal muscle insulin resistance does not require NF-κB activation

Pascal P. H. Hommelberg · Jogechum Plat · Lauren M. Sparks · Anemie M. W. J. Schols · Anon L. M. van Essen · Marco C. J. M. Kelders · Denis van Beurden · Ronald P. Mensink · Ramon C. J. Langen

Abstract Palmitate activates the NF-κB pathway, and induces accumulation of lipid metabolites and insulin resistance in skeletal muscle cells. Little information is available whether and how these processes are causally related. Therefore, the objectives were to investigate whether intra-cellular lipid metabolites are involved in FA-induced NF-κB activation and/or insulin resistance in skeletal muscle and to investigate whether FA-induced insulin resistance and NF-κB activation are causally related. Inhibiting DGAT or CPT-1 by using, respectively, amidepsine or etomoxir increased DAG accumulation and sensitized myotubes to palmitate-induced insulin resistance. While co-incubation of palmitate with etomoxir increased NF-κB transactivation, co-incubation with amidepsine did not, indicating that DAG accumulation is associated with insulin resistance but not with NF-κB activation.

Furthermore, pharmacological or genetic inhibition of the NF-κB pathway could not prevent palmitate-induced insulin resistance. In conclusion, we have demonstrated that activation of the NF-κB pathway is not required for palmitate-induced insulin resistance in skeletal muscle cells.

Keywords Skeletal muscle · Insulin resistance · Palmitate · Nuclear factor-kappa B · Glucose uptake

Introduction

Insulin resistance is recognized as an important risk factor in the development of type 2 diabetes, the prevalence of which is rapidly increasing [1]. Although it is generally accepted that this may relate to a Western-type diet high in saturated fatty acids [2], the detailed pathogenesis underlying the initiation of insulin resistance is still poorly understood. Since skeletal muscle is responsible for 70–80% of insulin-stimulated glucose uptake, skeletal muscle insulin resistance is most likely a major determinant of type 2 diabetes [3].

Type 2 diabetic patients are characterized by an elevation in plasma free fatty acids (FFA) [4]. These FFA play a major role in the pathogenesis of insulin resistance, since lowering FFA levels in the plasma significantly improves insulin sensitivity [5, 6], whereas lipid infusion leading to increased plasma FFA induces skeletal muscle insulin resistance in rodents and humans [7–9]. It is thought that circulating FFA interfere with insulin signaling as a consequence of cellular FA oversupply or impaired mitochondrial FA oxidation, leading to intra-muscular accumulation of FA metabolites. Increased levels of the lipid metabolite diacylglycerol (DAG) in skeletal muscle indeed accompanies diet-induced insulin resistance in...
rodents [10] and lipid infusion-induced insulin resistance in humans [8]. Whether DAG is the crucial trigger and via which cellular processes DAG accumulation leads to insulin resistance is still unclear. However, since DAG accumulation during lipid infusion coincides with nuclear factor kappa B (NF-κB) activation in insulin-resistant muscle, NF-κB has been implicated in the mechanism underlying FA-induced DAG-mediated muscular insulin resistance [8]. Although several in vitro studies in skeletal muscle provide evidence that long-chain saturated FA-induced insulin resistance coincides with DAG accumulation [11] and activation of the NF-κB pathway [12–14], little information is available if and how these processes are causally related. Therefore, the first objective of this study was to investigate whether DAG accumulation is involved in NF-κB activation and/or FA-induced insulin resistance in skeletal muscle by interfering with β-oxidation and DAG to TAG conversion.

Several studies in rodents and humans showed that insulin resistance induced by hyperlipidemia (lipid infusion) or an obesity-inducing high fat diet was associated with decreased IκBx protein levels in skeletal muscle, which is suggestive for NF-κB activation [8, 15, 16]. Furthermore, whole body inhibition of NF-κB activity by pharmacological means or by heterozygous deletion of the NF-κB-activating kinase IKK-2, prevented lipid infusion-, obesity- and diet-induced insulin resistance [17, 18], illustrating an important role for NF-κB in whole-body glucose homeostasis.

However, the specific contribution of NF-κB activation in skeletal muscle was not assessed in these studies. Mice with a muscle-specific inhibition of NF-κB by transgenic expression of the IκBx super-repressor (MISR mice) were not protected against the development of diet-induced whole body insulin resistance [19], and muscle-specific IKK-2 deficient mice showed no differences in whole body glucose homeostasis after gold thioglucose-induced obesity [20]. Since insulin resistance of other tissues could potentially mask a protective effect of NF-κB inhibition on muscle glucose homeostasis, in this respect, studies using cultured muscle cells are of great advantage. In L6 myotubes, it has been shown that palmitate-induced insulin resistance could be prevented by pharmacological inhibitors of IKK and NF-κB nuclear translocation in L6 myotubes [21, 22]. In contrast, non-saturated FA-induced NF-κB activation in absence of insulin resistance has been described in skeletal muscle [23]. Moreover, several studies showed that stimulation of muscle cells with TNF-α, a well-known and potent NF-κB activator, does not induce insulin resistance [24–26], while others showed that muscle-specific transgenic expression of activated IKK in mice (MIKK mice) [19] and over-expression of IKK-2 and p65 via in vivo electrotransfer in rat muscles does not induce insulin resistance [27]. From the latter studies, it appears that muscular NF-κB activation per se is not sufficient to induce insulin resistance.

Considering that these conflicting results regarding the requirement of muscular NF-κB activation in FA-induced insulin resistance may be attributable to differences in strategies to modulate NF-κB activity, the second objective of this study was to address the contribution of NF-κB activation to palmitate-induced insulin resistance in cultured skeletal muscle using both pharmacological and genetic approaches to inhibit NF-κB activity.

Materials and methods

Cell culture

The C2C12 murine skeletal muscle cell line (ATCC CRL1772, Manassas, VA), stably transfected with the 6κB-TK-luciferase, was used for the assessment of NFκB transcriptional activity. In brief, C2C12 cells were plated (1 × 10^4 cells/cm²) on growth factor reduced Matrigel (Becton–Dickinson Labware, Bedford, MA, USA) and 9% (vol/vol) fetal bovine serum (FBS; PAA Laboratories, UK). To induce differentiation, GM was replaced by differentiation medium (DMEM) dishes, as described previously [28]. C2C12 myoblasts were cultured in growth medium (GM), composed of low glucose DMEM containing antibiotics (50 U/ml penicillin and 50 μg/ml streptomycin; both from Gibco-Invitrogen, Rockville, MD, USA) and 9% (vol/vol) fetal bovine serum (FBS; PAA Laboratories, UK). To induce differentiation, GM was replaced by differentiation medium (DM), containing DMEM with 1% (vol/vol) heat-inactivated FBS and antibiotics. As a positive control for NF-κB transcriptional activity, murine TNFα (Calbiochem, San Diego, CA, USA) was added to the dishes.

Myoblasts from the L6 rat skeletal muscle cell line were cultured in GM, composed of α-MEM (Gibco-Invitrogen) containing 9% (vol/vol) FBS and antibiotics. The plating density used for the experiments was 2 × 10^5/cm². After 24 h of culturing in growth medium, differentiation was induced by replacing GM with DM, containing α-MEM with 2% (vol/vol) heat-inactivated FBS and antibiotics.

Amidepine A (Alexis, San Diego, CA, USA), etomoxir and parthenolide (both from Sigma, St. Louis, MO, USA) were added 30 min before palmitate incubations.

All experiments described for both cell lines were performed in 5- or 6-day differentiated myotubes unless stated otherwise.

Palmitate incubations

Palmitate (C16:0; Sigma) stock solutions of 40 mmol/l were prepared in ethanol. Before application to the cells,
palmitate was conjugated to bovine serum albumin (BSA) by diluting the palmitate solution with differentiation medium containing 1% (w/v) palmitate-free BSA (Sigma). Solutions were filter-sterilized before addition to the cells. Because of different sensitivities of both cell lines towards the maximal palmitate concentrations used were 200 μmol/l for L6 myotubes and 400 μmol/l for C2C12 myotubes.

Vehicle controls contained equal amounts of ethanol (max 1% in C2C12 or 0.5% in L6) (v/v) and BSA (1% (w/v)).

Diacylglycerol analysis

Freeze-dried L6 myotubes were extracted overnight at 4°C with chloroform–methanol (2:1 by volume), containing 10 mg/l of butylated hydroxytoluene. After centrifugation, the supernatant was evaporated under nitrogen gas. Lipids were reconstituted in chloroform–methanol (1:1), containing 10 mg/l of butylated hydroxytoluene, spotted onto TLC plates and developed in a solvent containing petroleum-benzin-diethyl ether-acetic acid (120:25:1.5 by volume). The DAG fractions were identified against a DAG standard (Sigma) and scraped into a vial. From the DAG extracts, methyl esters were prepared by transmethylation using a mixture of toluene-methanol-(BF3-methanol 14%) (20–55–25% by volume) at 100°C for 30 min. The fatty acid methyl esters were separated by capillary gas liquid chromatography using a 50 m × 0.25 mm CP-sil 88 silica column (Varian) with helium as carrier gas at a flow of 130 kPa. Fatty acids were identified by comparison with a standard mixture of fatty acid methyl esters.

Alternatively, cells were pre-incubated for 16 h with [1-14C] palmitate (0.5 μCi/ml; PerkinElmer, Boston, MA, USA) and respective non-labeled (cold) palmitate (100 μM). Following incubation, cells were washed twice with 1× PBS and harvested into 0.25 ml of 0.05% SDS for subsequent protein measurement and total lipid extraction with 1 ml of chloroform/methanol (2v/1v). Lipids were washed with 70% ethanol and re-dissolved for thin layer chromatography (TLC) (Anal Tech TLC plates; Whatman, Kent, ME, USA) and run in a mobile phase containing hexane/diethyl ether/acetic acid, v/v/v, 80:20:1). Bands corresponding diacylglycerol (DAG) were scraped and transferred into scintillation vials, and radioactivity was measured on a multipurpose scintillation counter (LS 6500; Beckman Coulter, Brea, CA, USA). All assays were performed in triplicate, and data were normalized to protein content.

Transfections and plasmids

Stable cell lines were created by transfection with Nanofectin (PAA) according to manufacturers’ recommendations.

To inhibit NF-κB activation, L6 myoblasts (3 × 10^3 cells/cm^2) were stably transfected with nanofectin in the presence of a plasmid encoding IxBz-SR (3 μg), which was constitutively expressed under control of the SFFV-LTR (pSFFV-NEO IxBz-SR), kindly provided by Dr. Rosa Ten (Mayo Clinic, Rochester, MN, USA). A control cell line was created using the same strategy, with plasmid DNA containing the neomycin resistance gene (pSV2-Neo; Stratagene, La Jolla, CA, USA). For selection of positive clones, cells were cultured in GM containing the presence of 800 μg/ml G-418 (Calbiochem).

NF-κB transcriptional activity

To determine NF-κB transcriptional activity, luciferase activity was measured in a NF-κB sensitive reporter cell line as previously described [28]. After the appropriate incubation time with the various stimuli, cells were washed twice with cold phosphate-buffered salin (PBS) and lysed by adding 100 μl 1× Reporter Lysis Buffer (Promega, Madison, WI, USA). After incubation on ice for 10 min, cell lysates were centrifuged (13,000g, 2 min) and stored at −80°C until analysis. Luciferase activity was measured according to the manufacturers’ instructions (Promega) and corrected for total protein content (Bio-Rad, Hercules, CA, USA).

Electrophoretic mobility shift analysis

To determine DNA binding activity of NF-κB, complexes binding to an oligonucleotide containing a NF-κB consensus sequence were analyzed by EMSA. Nuclear extracts were isolated to analyze NF-κB DNA binding. To this end, cells were harvested following experimental treatments and lysed on ice in 400 μl buffer containing 20 mmol/l HEPES, pH 7.8, 20 mmol/l KCl, 4 mmol/l MgCl2, 0.2 mmol/l EDTA, 1 mmol/l DTT, 0.2 mmol/l sodiumorthovanadate, 0.4 mmol/l phenylmethyl sulfonylfluoride, 0.3 μg/ml leupeptin and 0.2 mmol/l NaF for 15 min. Subsequently, 25 μl 10% Nonidet P40 was added and samples were vortexed for 15 s followed by centrifugation (14,000g for 30 s). Supernatants were removed and pelleted nuclei were washed with the previously mentioned buffers and resuspended with a buffer containing 100 mmol/l HEPES, pH 7.8, 100 mmol/l KCl, 600 mmol/l NaCl, 0.2 mmol/l EDTA, 20% glycerol, 1 mmol/l DTT, 0.2 mmol/l sodiumorthovanadate, 0.667 mmol/l phenylmethyl sulfonnylfuoride and 0.2 mmol/l NaF. Nuclei were mixed vigorously for 20 min at 4°C using a rotating platform, centrifuged (14,000g for 5 min) and samples were stored at −20°C (for protein concentration determination) and −80°C (for DNA binding activity measurements). 7 μg nuclear cell extracts were used per binding reaction, and
protein-DNA complexes were resolved on a 5% polyacrylamide gel in 0.25 × Tris borate-EDTA buffer at 160 V for 2 h. Gels were dried and exposed to film (X-Omat Blue XB-1; Kodak, Rochester, NY, USA). Shifted complexes were quantified by phosphoimager analysis (Bio-Rad). To determine the presence of RelA (p65) by supershift analysis, nuclear extracts were pre-incubated with an antibody specific to the RelA subunit of NF-κB (Santa Cruz Biotechnology).

[3H]deoxyglucose uptake

Basal and insulin-dependent deoxyglucose uptake was determined as described previously [12]. In brief, L6 myotubes with or without FA preincubation were serum deprived for 3 h prior to incubation with 25 nmol/l insulin (Sigma) for 15 min at 37°C in glucose-free medium. Label (0.2 μCi/ml [3H]deoxyglucose) was added (final concentration of 20 μmol/l) and incubated for 20 min at 37°C. Glucose transport was terminated by washing three times with an ice-cold stop-solution containing 0.2 mmol/l phloretin and cells were harvested in 0.5 ml 0.05 mol/l NaOH. Cell-associated radioactivity was determined by scintillation counting.

Statistical analysis

SPSS (version 16.0) was used for statistical analysis. Data were analyzed by one-way ANOVA, and the various treatment groups were compared by using the post-hoc Bonferroni test in which a $P < 0.05$ was considered statistically significant. Data is presented as means ± SD. Data shown are representative examples of three independent experiments.

Results

Palmitate induces insulin resistance, DAG accumulation and NF-κB activation in myotubes

Verifying previous findings considering palmitate-induced insulin resistance, L6 myotubes were treated for 16 h with 200 μmol/l palmitate. As expected, incubation with palmitate suppressed insulin-stimulated deoxyglucose uptake compared with untreated cells (Fig. 1a). This palmitate-induced insulin resistance coincided with a fivefold increase in diacylglycerol (DAG) accumulation (Fig. 1b). To determine the effects of palmitate incubation on NF-κB

![Fig. 1](image)

**Fig. 1** Palmitate induces insulin resistance, DAG accumulation and NF-κB transactivation in myotubes. **a** L6 myoblasts were differentiated for 5 days and subsequently incubated for 16 h with and without 200 μmol/l palmitate prior to stimulation with 25 nmol/l insulin for 15 min (white bars no insulin stimulation; black bars insulin stimulation). 2-deoxyglucose uptake was measured as described in “Materials and methods”, and insulin-stimulated glucose uptake was expressed as fold induction over basal (non-insulin stimulated) glucose uptake. *$P < 0.05$. Alternatively, L6 myotubes were incubated with 200 μmol/l palmitate for 16 h, after which DAG accumulation was determined by thin layer chromatography, corrected for protein content and expressed as fold change to control, or **c** NF-κB DNA binding was determined by EMSA, as described in “Materials and methods”, and expressed as fold induction over control. *$P < 0.05$. **d** Alternatively, C2C12 myoblasts stably transfected with the 6κB-TK-luciferase construct were differentiated for 5 days and incubated with 400 μmol/l palmitate for 24 h. Lysates were prepared for assessment of luciferase activity. Values were corrected for protein content and expressed as fold-induction over control. *$P < 0.05$
activation, NF-κB DNA binding was investigated in L6 myotubes. Palmitate treatment resulted in a ~3.2-fold increase in DNA binding (Fig. 1c). To test whether the increased DNA binding led to an increased NF-κB transactivation, we measured transcriptional activity in C2C12 myotubes, stably transfected with a NF-κB sensitive reporter construct. Palmitate increased NF-κB dependent luciferase activity (Fig. 1d), which confirmed the DNA binding results in L6 myotubes.

Blocking β-oxidation sensitizes myotubes to palmitate-induced insulin resistance and NF-κB transactivation

Impaired FA oxidation causes lipid accumulation in skeletal muscle [29]. To assess the effects of intramyocellular lipid (IMCL) accumulation on insulin sensitivity and NF-κB activity, FA-oxidation was inhibited by blocking carnitine palmitoyltransferase-1 (CPT-1), an enzyme mediating the transport of long chain fatty acids across the mitochondrial membrane. Myotubes were incubated with 80 μmol/l etomoxir, an irreversible inhibitor of CPT-1 [30]. Supplementary Fig. 1 demonstrates that this concentration of etomoxir resulted in a ~twofold increase in DAG accumulation in presence of 100 μmol/l palmitate. Treatment of etomoxir without additional FA had no effects on insulin-induced glucose uptake (Fig. 2a). Also treatment of myotubes with the low concentration of 100 μmol/l palmitate alone had no effects on insulin sensitivity, while increasing the palmitate concentrations resulted as expected in a reduced insulin-induced glucose uptake. In contrast, co-incubation of palmitate and etomoxir already reduced insulin-stimulated glucose uptake at 100 μmol/l palmitate. Moreover, inhibition of β-oxidation, inducing DAG accumulation, further enhanced the insulin resistance induced by increasing palmitate concentrations.

To investigate if sensitization to palmitate-induced insulin resistance by etomoxir coincided with enhanced NF-κB activation, we determined the effect of co-incubation of etomoxir and palmitate on NF-κB transactivation activity (Fig. 2b). Again, etomoxir and 100 μmol/l palmitate alone had no effect compared to control, while co-incubation with these two agents simultaneously resulted in an increased NF-κB transactivation activity. Palmitate increased NF-κB transactivation activity in a dose-responsive manner, whereas etomoxir had a synergistic effect, as it further enhanced (an additional 1.4–1.8 fold) palmitate-induced NF-κB activation. These data reveal that inhibition of β-oxidation sensitizes myotubes to palmitate-induced NF-κB activation and insulin resistance, and suggest that NF-κB activation and insulin resistance are coupled under conditions of DAG accumulation.

Segregation of palmitate-induced NF-κB transactivation and insulin resistance following inhibition of DAG conversion

Diacylglycerol acyltransferase (DGAT) is an enzyme involved in the formation of triglycerides from diacylglycerol (DAG) and acyl-CoA in insulin-sensitive tissues like skeletal muscle. In a second approach to study the effects of DAG accumulation on NF-κB activation and insulin resistance, we used the DGAT inhibitor amidepsine [31]. Amidepsine significantly increased DAG
accumulation (supplementary Fig. 1) in L6 myotubes. Treatment of myotubes with 10 μg/ml (~8.8 μmol/l) amidepsine in absence of palmitate did not affect insulin-induced glucose uptake (Fig. 3a). However, in line with the effects of etomoxir treatment, amidepsine sensitized myotubes to palmitate-induced insulin resistance, and co-incubation of 150 μmol/l palmitate with amidepsine already completely abolished insulin-mediated glucose uptake. In contrast to the effects of etomoxir, amidepsine treatment did not further increase, but even slightly reduced palmitate-induced NF-κB transcriptional activity (Fig. 3b), despite a significant increase (38% compared to palmitate without amidepsine, \( P = 0.004 \)) in C2C12 myotubes. These findings reveal segregation of palmitate-induced DAG accumulation, insulin resistance and NF-κB activation following inhibition of DAG conversion, and suggest that NF-κB may not be required for palmitate-induced insulin resistance.

Pharmacological or genetic inhibition of NF-κB does not prevent palmitate-induced insulin resistance in myotubes

To test whether the NF-κB pathway is causally linked to palmitate-induced insulin resistance, pharmacological and genetic approaches were employed to inhibit NF-κB. First, C2C12 myotubes were incubated with 20 μmol/l parthenolide, an agent that inhibits NF-κB activation by inhibiting IKK activity [32]. The NF-κB inhibitory capacity of parthenolide was confirmed as it blocked TNFα-induced NF-κB activity in myotubes (data not shown). Parthenolide resulted in a complete abolishment of palmitate-induced NF-κB transcriptional activity (Fig. 4a). In spite of this potent NF-κB inhibitory capacity, the palmitate-induced reduction of glucose uptake could not be prevented by parthenolide (Fig. 4b), which—in line with the amidepsine findings—suggests that palmitate-induced NF-κB activation and insulin resistance are not causally related.

To further confirm these findings, we also inhibited the NF-κB pathway by genetic modification, using IκBα-SR, a non-degradable mutant of IκBα. As expected, increased NF-κB DNA binding after treatment with palmitate (Fig. 5a) or TNFα (data not shown) was not observed in L6 cells expressing the IκBα-SR super repressor (SR), in contrast to control myotubes. In complete accordance with the parthenolide results, there was no improvement in insulin-induced glucose uptake in IκBα-SR myotubes treated with palmitate (Fig. 5b). Thus, neither pharmacological and genetic blockade of NF-κB could prevent palmitate-induced insulin resistance in skeletal muscle cells, illustrating NF-κB activity in skeletal muscle is not required for palmitate-induced insulin resistance.

Discussion

Lipid infusion-induced insulin resistance in human skeletal muscle is associated with an increase in diacylglycerol (DAG) mass and a reduction in IκBα protein levels [8]. This led to the suggestion that DAG accumulation, NF-κB activation and insulin resistance are causally related. Here, we show that palmitate-induced insulin resistance in
skeletal muscle cells indeed coincides with increased NF-κB activation and DAG accumulation. However, our intramyocellular lipid metabolite modulating experiments uncoupled the effects of palmitate-induced DAG accumulation and insulin resistance from NF-κB activation. Furthermore, pharmacological and genetic inhibition of the NF-κB pathway could not prevent the palmitate-induced reduction in insulin-stimulated glucose uptake. Altogether, this implies that NF-κB activation is not a causal factor in palmitate-induced insulin resistance in skeletal muscle.

FA oversupply results in increased intra-myocellular lipid (IMCL) and consequent lipid metabolite accumulation, and this was reproduced by pharmacological inhibition of carnitine palmitoyltransferase 1 (CPT-1) using etomoxir. By irreversible inhibition of CPT-1, etomoxir is able to block the entry of long-chain fatty acyl-CoA into mitochondria [30, 33, 34]. Consequently, CPT-1 inhibition results in intramyocellular lipid (IMCL) accumulation [29] and may therefore lead to cytoplasmatic accumulation of lipid metabolites, like palmitoyl-CoA, DAG and ceramide, which have all been implicated in the pathogenesis of insulin resistance in skeletal muscle [8, 11, 35–39]. Indeed, treatment with etomoxir sensitized myotubes to palmitate-induced DAG accumulation and insulin resistance, causing decreased insulin-stimulated glucose uptake even with non-insulin resistance-inducing palmitate concentrations. These results are in agreement with a study in rats, where inhibition of CPT-1 by prolonged etomoxir administration resulted in increased IMCL accumulation, associated with insulin resistance [29]. Furthermore, CPT-1 over-expression in L6E9 muscle cells prevented DAG and ceramide accumulation and activation of protein kinase C (PKC)-ζ after palmitate incubation, and resulted in protection from palmitate-induced insulin resistance [40].
Another approach to manipulate accumulation of lipid metabolites is by inhibiting diacylglycerol acyltransferase (DGAT), the enzyme facilitating binding of DAG to long-chain acyl-CoAs to form triacylglycerol (TAG), using amidepsine A \[31, 41\]. In accordance with the etomoxir results, we found that inhibiting DGAT by amidepsine A resulted in DAG accumulation and sensitized myotubes to palmitate-induced insulin resistance. In line with this, over-expression of DGAT1 in skeletal muscle of mice resulted in protection against high fat diet-induced insulin resistance, which coincided with decreased DAG and ceramide levels and increased TAG levels \[42\]. This was associated with attenuated fat-induced activation of JNK and DAG-responsive PKCs. Furthermore, the same authors showed that, in isolated soleus muscle from DGAT knockout mice, the insulin-induced reduction in glucose uptake after administration of a palmitate/oleate mixture is exacerbated compared to wild-type muscle, which coincided with increased DAG and ceramide levels. Conversely, muscles over-expressing DGAT1 showed enhanced insulin sensitivity, associated with decreased DAG and ceramide levels (comparable to muscle from wild-type mice) \[42\]. Whether DAG or ceramides are responsible for palmitate-induced insulin resistance cannot be concluded from our experiments, since accumulation of palmitoyl-CoA might not only lead to the formation of DAG, but also to ceramides. Since palmitoyl-CoA is a precursor in sphingolipid synthesis \[43\], etomoxir or amidepsine treatment may lead to enhanced ceramide synthesis, as has been reported for etomoxir in hematopoietic cell lines \[44\].

While etomoxir alone did not induce NF-κB activation, it did increase NF-κB transactivation when co-incubated with 100 μmol/l palmitate. However, in contrast to etomoxir, direct interference with DAG metabolism by inhibiting the conversion from DAG to TAG with amidepsine did not increase palmitate-induced NF-κB transactivation. Based on these results, it is unlikely that DAG or DAG-induced PKC activation is responsible for NF-κB activation as DAG accumulation was observed in response to both etomoxir and amidepsine. Ceramides are known activators of NF-κB \[45, 46\] and are therefore a likely candidate for the observed NF-κB activation in response to palmitate.

Moreover, these differential effects of lipid metabolite modulation on insulin resistance and NF-κB activation suggest that FA-induced insulin resistance and NF-κB activation in skeletal muscle are not related. This dissociation between FA-induced NF-κB activity and insulin resistance was also postulated in a recent study from our group \[23\], in which we showed that several unsaturated fatty acids were able to increase NF-κB DNA binding and transcriptional activity in myotubes without inducing insulin resistance, which further supports that fatty acid-induced insulin resistance and NF-κB activation in muscle may occur independently.

Several studies in rodents and humans show that fat-induced insulin resistance is associated with NF-κB activation in skeletal muscle \[8, 15, 16\]. Although previous associations between palmitate-induced insulin resistance and NF-κB activation in skeletal muscle cells have also been reported \[12, 14\], we now show by pharmacological and by genetic inhibition that a causal relationship between both processes can be ruled out.

Previous studies investigating this potential association used inhibition of IKK by high doses of salicylate or by heterozygous deletion, which prevented lipid infusion-, obesity- and diet-induced insulin resistance in skeletal muscle \[17, 18\]. However, it has been shown that salicylate may reverse TNF-α-induced insulin resistance independently of IKK-2/NF-κB inhibition \[47\]. In this study, salicylate inhibited JNK activation, and the latter has also implicated in obesity-induced insulin resistance \[48\]. Furthermore, there is evidence from several in vivo studies that the NF-κB pathway in skeletal muscle is not required for high-fat diet-induced insulin resistance. Muscle-specific inhibition of NF-κB by transgenic expression of the IκBα super-repressor (MISR mice) did not protect against the development of obesity-induced insulin resistance, following a high fat diet for 3 months \[19\]. Muscle-specific IKK-2-deficient mice were not protected against whole body or muscle insulin resistance induced by gold thioglucose or high-fat \[20\]. Taken together, these in vivo studies suggest that activation of the NF-κB pathway in muscle does not seem to play a causal role in high-fat-induced insulin resistance.

In fact, the evidence causally relating FA-induced insulin resistance in muscle to NF-κB activation is entirely derived from in vitro studies using L6 skeletal muscle cells \[21\], in which it was shown that pharmacological inhibition of IKK (using parthenolide and acetylsalicylate) or blockade of nuclear translocation of NF-κB prevented palmitate-induced reductions in insulin-stimulated glucose uptake. The acetylsalicylate-induced effects on insulin resistance may be IKK independent, since it is known that acetylsalicylate blocks several kinases, including JNK, \[49\], which as pointed out above has been implicated in insulin resistance. In addition, SN50, a peptide used to block nuclear import of NF-κB \[50\], was used as proof that nuclear translocation of NF-κB is required for the insulin-desensitizing effects of palmitate \[21\]. However, these data should be interpreted with care as SN50 displays inhibitory activity towards the nuclear translocation of a range of transcription factors other than NF-κB \[51\]. Importantly, SN50 also blocks nuclear import of activator protein (AP)-1, which is a JNK-responsive transcription factor, suggesting that reversal of insulin resistance by SN50 can also be explained by inhibition of the JNK/AP-1 pathway which has been implicated in insulin resistance \[48\].
Insulin resistance is independent of NF-κB

In contrast to the observations concerning reversal of insulin sensitivity following NF-κB inhibition by parthenolide [21], in our hands parthenolide, despite complete ablation of NF-κB activation, displayed no protection against palmitate-induced insulin resistance. Although it is difficult to reconcile these opposing findings, we are confident of our data as a second, genetic approach to inhibit NF-κB yielded identical results. Here, we showed that complete ablation of NF-κB activity by IκBα-SR in L6 cells did not prevent palmitate-induced insulin resistance. A similar strategy to inhibit muscular NF-κB activation also ruled out a role of muscle NF-κB in high-fat-induced insulin resistance [19]. Although insulin resistance of other tissues could potentially have masked a protective effect of NF-κB inhibition in muscle as whole body insulin sensitivity was measured in that study, our findings further extend the evidence against an important role for NF-κB in skeletal muscle insulin resistance as insulin sensitivity was measured directly in cultured muscle. Finally, in line with previous reports [24–26], LPS and TNF-α were not able to induce insulin resistance in myotubes despite potent NF-κB activation (data not shown). This further confirms findings that muscle-specific NF-κB activation is not sufficient to induce insulin resistance [19, 52], and underlines the notion that NF-κB activation and insulin resistance in skeletal muscle are not causally related.

In conclusion, we demonstrate that manipulation of DAG accumulation by inhibiting DGAT or β-oxidation resulted in segregation of palmitate-induced insulin resistance and NF-κB activation, suggesting that these processes are not related. By pharmacological and genetic inhibition of the NF-κB pathway, we reveal that activation of the NF-κB pathway is not required for palmitate-induced insulin resistance in skeletal muscle cells.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782–787
2. Parker DR, Weiss ST, Troisi R, Cassano PA, Vokonas PS, Landsberg L (1993) Relationship of dietary saturated fatty acids and body habitus to serum insulin concentrations: the normative aging study. Am J Clin Nutr 58:129–136
3. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP (1981) The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 30:1000–1007
4. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD (1988) Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 37:1020–1024
5. Qvigstad E, Mostad IL, Bjerve KS, Grill VE (2003) Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects. Am J Physiol Endocrinol Metab 284:E129–E137
6. Ahren B (2001) Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice. Acta Physiol Scand 171:161–167
7. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GT, Atcheson B, White MF, Kraegen EW, Shulman GI (2002) Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 277:50230–50236
8. Itani SI, Ruderman NB, Schmieder F, Boden G (2002) Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκappaB-alpha. Diabetes 51:2005–2011
9. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, White MF, Shulman GI (1999) Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48:1270–1274
10. Lee JS, Finnemann SK, Eo SJ, Cho IH, Pyo JH, Kim CK, Sinclair AJ, Febbraio MA, Watt MJ (2006) Saturated, but not n-6 polyunsaturated fatty acids induce insulin resistance: role of intramuscular accumulation of lipid metabolites. J Appl Physiol 100:1467–1474
11. Chavez JA, Summers SA (2003) Characterizing the effects of saturated fatty acids on insulin signaling and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch Biochem Biophys 419:101–109
12. Hommelberg PP, Plat J, Langen RC, Schols AM, Mensink RP (2009) Fatty acid-induced NF-κB activation and insulin resistance in skeletal muscle are chain length dependent. Am J Physiol Endocrinol Metab 296:E114–E120
13. Weigert C, Brodbeck K, Staiger H, Kausch C, Machicao F, Haring HU, Schleicher ED (2004) Palmitate, but not unsaturated fatty acids, induces the expression of interleukin-6 in human myotubes through proteasome-dependent activation of nuclear factor-kappaB. J Biol Chem 279:23942–23952
14. Jove M, Planavila A, Sanchez RM, Merlos M, Laguna JC, Vazquez-Carrera M (2006) Palmitate induces tumor necrosis factor-alpha expression in C2C12 skeletal muscle cells by a mechanism involving protein kinase C and nuclear factor-kappaB activation. Endocrinology 147:552–561
15. Bhatt BA, Dube JJ, Dedoussis N, Reider JA, O’Doherty RM (2006) Diet-induced obesity and acute hyperlipidemia reduce IκappaB alpha levels in rat skeletal muscle in a fiber-type dependent manner. Am J Physiol Regul Integr Comp Physiol 290:R233–R240
16. Ropelle ER, Pauli JR, Prada PO, de Souza CT, Picardi PK, Faria MC, Cintra DE, Fernandes MF, Flores MB, Velloso LA, Saad MJ, Carvalheira JB (2006) Reversal of diet-induced insulin resistance with a single bout of exercise in the rat: the role of PTP1B and IRS-1 serine phosphorylation. J Physiol 577:997–1007
17. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293:1673–1677
18. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI (2001) Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 108:437–446
19. Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE (2004) IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119:285–298
20. Rohl M, Pasparakis M, Baudler S, Baumgartl J, Gautam D, Huth M, De Lorenzi R, Krone W, Rajewsky K, Brunning JC (2004) Conditional disruption of IkappaB kinase 2 fails to prevent obesity-induced insulin resistance. J Clin Invest 113:474–481
21. Sinha S, Perdomo G, Brown NF, O’Doherty RM (2004) Fatty acid-induced insulin resistance in islets myobutides is prevented by inhibition of activation and nuclear localization of nuclear factor kB. J Biol Chem 279:41294–41301
22. Radin MS, Sinha S, Bhatt BA, Dedousis N, O’Doherty RM (2004) Inhibition or deletion of the lipopolysaccharide receptor Toll-like receptor-4 confers partial protection against lipid-induced insulin resistance in rodent skeletal muscle. Diabetologia 51:336–346
23. Hommelberg PP, Langen RC, Schols AM, van Essen AL, Snepvangers FJ, Mensink RP, Plat J (2010) Trans fatty acid-induced NF-kappaB activation does not induce insulin resistance in cultured murine skeletal muscle cells. Lipids 45:285–290
24. Roher N, Samokhvalov V, Diaz M, MacKenzie S, Klip A, Planas JV (2008) The proinflammatory cytokine tumor necrosis factor-alpha increases the amount of glucose transporter-4 at the surface of muscle cells independently of changes in interleukin-6. Endocrinology 149:1880–1889
25. Lee MD, Zentella A, Patel W, Pekala PH, Cerami A (1987) Characterization of the mitochondrial carnitine palmitoyltransferase enzyme system I. Use of inhibitors. J Biol Chem 262:6214–6224
26. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
27. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
28. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
29. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
30. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
31. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
32. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
33. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
34. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
35. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
36. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
37. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
38. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
39. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
40. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
41. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
42. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
43. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
44. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
45. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
46. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
47. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
48. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
49. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
50. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
51. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
52. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
53. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
54. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
55. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
56. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
57. Morrow JP, Cao G, Yang XL, Stamler JS (1998) Nitric oxide competitively inhibits superoxide anion production by neutrophils. Proc Natl Acad Sci USA 95:5483–5487
51. Torgerson TR, Colosia AD, Donahue JP, Lin YZ, Hawiger J (1998) Regulation of NF-kappa B, AP-1, NFAT, and STAT1 nuclear import in T lymphocytes by noninvasive delivery of peptide carrying the nuclear localization sequence of NF-kappa B p50. J Immunol 161:6084–6092

52. Polkinghorne E, Lau Q, Cooney GI, Kraegen EW, Cleasby ME (2008) Local activation of the IkappaK-NF-kappaB pathway in muscle does not cause insulin resistance. Am J Physiol Endocrinol Metab 294:E316–E325